BioCardia (NASDAQ: BCDA) CEO adds 1,700 shares in May open‑market buys

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s common stock. He bought 200 shares at $0.95 per share on May 19, 2026 and 1,500 shares at $0.92 per share on May 20, 2026. After these transactions, he directly owns 293,266 shares of BioCardia common stock.

Insider Trade Summary

Net Buyer: 1,700 shares ($1,570)

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 1,700 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,500	$0.92	$1K
Purchase	Common Stock	200	$0.95	$190.00

Holdings After Transaction: Common Stock — 293,266 shares (Direct, null)

Footnotes (1)

1. This transaction was executed in multiple trades ranging from $0.9506 to $0.9508 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. This transaction was executed in multiple trades ranging from $0.91 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased May 19, 2026: 200 shares at $0.95/share Shares purchased May 20, 2026: 1,500 shares at $0.92/share Total shares bought: 1,700 shares +1 more

4 metrics

Shares purchased May 19, 2026 200 shares at $0.95/share Open-market purchase of common stock

Shares purchased May 20, 2026 1,500 shares at $0.92/share Open-market purchase of common stock

Total shares bought 1,700 shares Net buy across two transactions

Shares owned after transactions 293,266 shares Direct holdings of common stock post-trade

Key Terms

open-market purchase, weighted average per share sales price, transaction code "P", beneficial ownership

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price."

transaction code "P" financial

"transaction_code: "P" with description Purchase in open market or private transaction"

beneficial ownership financial

"full information regarding the number shares purchased at each separate price."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		P		200(1)	A	$0.95(1)	291,766	D
Common Stock	05/20/2026		P		1,500(2)	A	$0.92(2)	293,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.9506 to $0.9508 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $0.91 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did BioCardia (BCDA) report for Peter Altman?

Peter Altman reported two open-market purchases of BioCardia common stock, totaling 1,700 shares. He bought 200 shares at $0.95 on May 19, 2026, and 1,500 shares at $0.92 on May 20, 2026, increasing his direct holdings.

At what prices did the BioCardia (BCDA) CEO buy shares in the latest Form 4?

Peter Altman bought BioCardia shares at weighted average prices of $0.95 and $0.92 per share. Footnotes explain each transaction was executed in multiple trades within narrow price ranges, with the reported prices reflecting weighted averages across those trades.

How many BioCardia (BCDA) shares does Peter Altman hold after these transactions?

Following the reported purchases, Peter Altman directly holds 293,266 shares of BioCardia common stock. The Form 4 indicates these are direct holdings, giving investors a clear snapshot of his post-transaction ownership position in the company.

Were the recent BioCardia (BCDA) insider trades open-market purchases or something else?

Both reported transactions were coded "P" as open-market purchases of common stock. The Form 4 describes them as purchases in open market or private transactions, rather than option exercises, gifts, or tax-withholding dispositions, highlighting straightforward buying activity.

Do the BioCardia (BCDA) Form 4 footnotes reveal anything about trade pricing?

Yes. The footnotes state each transaction occurred through multiple trades within specified price ranges. The reported per-share prices are weighted averages of those trades, and the reporting person undertakes to provide detailed trade-by-trade information to regulators or security holders upon request.